Genmab A/S (OTCMKTS:GNMSF) Share Price Passes Above Fifty Day Moving Average – Should You Sell?

Genmab A/S (OTCMKTS:GNMSF) shares crossed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $326.52 and traded as high as $330.63. Genmab A/S shares last traded at $330.63, with a volume of 70 shares traded.

Genmab A/S Price Performance

The business has a 50 day moving average price of $326.52 and a 200 day moving average price of $292.43.

Genmab A/S (OTCMKTS:GNMSF) last released its quarterly earnings data on Thursday, November 6th. The company reported $6.46 earnings per share for the quarter, topping the consensus estimate of $4.86 by $1.60. Genmab A/S had a net margin of 41.36% and a return on equity of 23.98%. The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1 billion.

Genmab A/S Company Profile

Genmab A/S is a biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer and other serious diseases. The company’s core expertise lies in its proprietary antibody platforms, including DuoBody®, HexaBody® and HexElect®, which enable the design and engineering of novel bispecific and enhanced-effector antibodies. Genmab’s science-driven approach integrates advanced protein engineering with insights into tumor biology to generate candidates that can engage the immune system, disrupt disease pathways and offer potential safety and efficacy advantages over conventional therapies.

Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab has grown into a global organization with research and development facilities in Utrecht, the Netherlands, and commercial and clinical support offices in the United States.